Cargando…

Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients

OBJECTIVES: Advanced glycation end products (AGEs) are involved in the pathogenesis and complications of diabetes mellitus (DM). Gestational DM (GDM) is characterized by increased glycemia and oxidative stress, which are factors associated with high serum AGE concentrations. The aim of this study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lobo, João Paulo, Brescansin, Catiane Pompilio, Santos-Weiss, Izabella C. R., Welter, Marciane, de Souza, Emanuel Maltempi, Rego, Fabiane Gomes de Moraes, Picheth, Geraldo, Alberton, Dayane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118810/
https://www.ncbi.nlm.nih.gov/pubmed/28225992
http://dx.doi.org/10.1590/2359-3997000000238
_version_ 1785028880609837056
author Lobo, João Paulo
Brescansin, Catiane Pompilio
Santos-Weiss, Izabella C. R.
Welter, Marciane
de Souza, Emanuel Maltempi
Rego, Fabiane Gomes de Moraes
Picheth, Geraldo
Alberton, Dayane
author_facet Lobo, João Paulo
Brescansin, Catiane Pompilio
Santos-Weiss, Izabella C. R.
Welter, Marciane
de Souza, Emanuel Maltempi
Rego, Fabiane Gomes de Moraes
Picheth, Geraldo
Alberton, Dayane
author_sort Lobo, João Paulo
collection PubMed
description OBJECTIVES: Advanced glycation end products (AGEs) are involved in the pathogenesis and complications of diabetes mellitus (DM). Gestational DM (GDM) is characterized by increased glycemia and oxidative stress, which are factors associated with high serum AGE concentrations. The aim of this study was to evaluate the utility of a serum fluorescence AGE (F-AGE) method as a screening tool for gestational diabetes. SUBJECTS AND METHODS: Serum samples from 225 GDM patients and 217 healthy pregnant women (healthy controls) were diluted 50-fold in phosphate-buffered saline, and the AGEs were estimated by fluorometric analysis (λ(Ex) 350 nm/ λ(Em) 440 nm). RESULTS: No significant (P > 0.05) differences in AGE concentrations, expressed in Arbitrary Units (UA/mL × 10(4)), were observed in the women with GDM or in the healthy controls. Furthermore, F-AGE concentrations did not change significantly during the pregnancy (12-32 weeks of gestation). Only the GDM group had a positive correlation (r = 0.421; P < 0.001) between F-AGEs and serum creatinine concentrations. CONCLUSION: It was not possible to distinguish women with gestational diabetes from the healthy controls on the basis of serum F-AGE concentrations.
format Online
Article
Text
id pubmed-10118810
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Sociedade Brasileira de Endocrinologia e Metabologia
record_format MEDLINE/PubMed
spelling pubmed-101188102023-04-21 Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients Lobo, João Paulo Brescansin, Catiane Pompilio Santos-Weiss, Izabella C. R. Welter, Marciane de Souza, Emanuel Maltempi Rego, Fabiane Gomes de Moraes Picheth, Geraldo Alberton, Dayane Arch Endocrinol Metab Articles OBJECTIVES: Advanced glycation end products (AGEs) are involved in the pathogenesis and complications of diabetes mellitus (DM). Gestational DM (GDM) is characterized by increased glycemia and oxidative stress, which are factors associated with high serum AGE concentrations. The aim of this study was to evaluate the utility of a serum fluorescence AGE (F-AGE) method as a screening tool for gestational diabetes. SUBJECTS AND METHODS: Serum samples from 225 GDM patients and 217 healthy pregnant women (healthy controls) were diluted 50-fold in phosphate-buffered saline, and the AGEs were estimated by fluorometric analysis (λ(Ex) 350 nm/ λ(Em) 440 nm). RESULTS: No significant (P > 0.05) differences in AGE concentrations, expressed in Arbitrary Units (UA/mL × 10(4)), were observed in the women with GDM or in the healthy controls. Furthermore, F-AGE concentrations did not change significantly during the pregnancy (12-32 weeks of gestation). Only the GDM group had a positive correlation (r = 0.421; P < 0.001) between F-AGEs and serum creatinine concentrations. CONCLUSION: It was not possible to distinguish women with gestational diabetes from the healthy controls on the basis of serum F-AGE concentrations. Sociedade Brasileira de Endocrinologia e Metabologia 2017-01-27 /pmc/articles/PMC10118810/ /pubmed/28225992 http://dx.doi.org/10.1590/2359-3997000000238 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
Lobo, João Paulo
Brescansin, Catiane Pompilio
Santos-Weiss, Izabella C. R.
Welter, Marciane
de Souza, Emanuel Maltempi
Rego, Fabiane Gomes de Moraes
Picheth, Geraldo
Alberton, Dayane
Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients
title Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients
title_full Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients
title_fullStr Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients
title_full_unstemmed Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients
title_short Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients
title_sort serum fluorescent advanced glycation end (f-age) products in gestational diabetes patients
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118810/
https://www.ncbi.nlm.nih.gov/pubmed/28225992
http://dx.doi.org/10.1590/2359-3997000000238
work_keys_str_mv AT lobojoaopaulo serumfluorescentadvancedglycationendfageproductsingestationaldiabetespatients
AT brescansincatianepompilio serumfluorescentadvancedglycationendfageproductsingestationaldiabetespatients
AT santosweissizabellacr serumfluorescentadvancedglycationendfageproductsingestationaldiabetespatients
AT weltermarciane serumfluorescentadvancedglycationendfageproductsingestationaldiabetespatients
AT desouzaemanuelmaltempi serumfluorescentadvancedglycationendfageproductsingestationaldiabetespatients
AT regofabianegomesdemoraes serumfluorescentadvancedglycationendfageproductsingestationaldiabetespatients
AT pichethgeraldo serumfluorescentadvancedglycationendfageproductsingestationaldiabetespatients
AT albertondayane serumfluorescentadvancedglycationendfageproductsingestationaldiabetespatients